TraWell Co SpA
MIL:TWL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TraWell Co SpA
MIL:TWL
|
IT |
|
Tanvex BioPharma Inc
TWSE:6541
|
KY |
Balance Sheet
Balance Sheet Decomposition
TraWell Co SpA
TraWell Co SpA
Balance Sheet
TraWell Co SpA
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
1
|
2
|
2
|
1
|
2
|
3
|
6
|
3
|
3
|
5
|
5
|
4
|
4
|
|
| Cash |
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
2
|
1
|
2
|
3
|
6
|
3
|
3
|
5
|
5
|
4
|
4
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
2
|
1
|
1
|
2
|
0
|
0
|
1
|
1
|
0
|
|
| Total Receivables |
1
|
1
|
0
|
0
|
1
|
1
|
3
|
6
|
4
|
6
|
4
|
5
|
5
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
1
|
0
|
2
|
3
|
1
|
2
|
4
|
3
|
4
|
|
| Other Receivables |
0
|
1
|
0
|
0
|
1
|
1
|
1
|
3
|
2
|
4
|
0
|
2
|
1
|
|
| Inventory |
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
0
|
1
|
2
|
0
|
1
|
0
|
2
|
1
|
1
|
|
| Total Current Assets |
2
|
4
|
4
|
3
|
6
|
6
|
13
|
13
|
9
|
12
|
12
|
11
|
12
|
|
| PP&E Net |
2
|
3
|
4
|
4
|
4
|
4
|
4
|
4
|
3
|
3
|
16
|
14
|
11
|
|
| Intangible Assets |
0
|
1
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Goodwill |
12
|
13
|
12
|
12
|
12
|
12
|
22
|
23
|
15
|
15
|
12
|
12
|
11
|
|
| Note Receivable |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
3
|
2
|
2
|
3
|
3
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Other Assets |
12
|
13
|
12
|
12
|
12
|
12
|
22
|
23
|
15
|
15
|
12
|
12
|
11
|
|
| Total Assets |
17
N/A
|
22
+32%
|
22
-2%
|
22
0%
|
24
+11%
|
26
+7%
|
43
+67%
|
44
+2%
|
30
-32%
|
33
+10%
|
45
+35%
|
41
-7%
|
37
-9%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
3
|
4
|
3
|
4
|
0
|
0
|
0
|
7
|
3
|
2
|
4
|
4
|
4
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
2
|
1
|
0
|
0
|
1
|
3
|
4
|
2
|
3
|
3
|
3
|
|
| Other Current Liabilities |
0
|
1
|
2
|
3
|
5
|
5
|
5
|
2
|
2
|
3
|
6
|
6
|
6
|
|
| Total Current Liabilities |
4
|
6
|
7
|
8
|
7
|
7
|
9
|
14
|
10
|
9
|
14
|
15
|
16
|
|
| Long-Term Debt |
0
|
0
|
2
|
3
|
3
|
1
|
8
|
7
|
10
|
12
|
9
|
6
|
5
|
|
| Deferred Income Tax |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
1
|
0
|
0
|
0
|
0
|
3
|
2
|
2
|
3
|
4
|
3
|
4
|
|
| Other Liabilities |
0
|
1
|
1
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
11
|
9
|
6
|
|
| Total Liabilities |
5
N/A
|
8
+61%
|
11
+32%
|
12
+15%
|
13
+5%
|
10
-21%
|
20
+97%
|
24
+21%
|
23
-2%
|
25
+7%
|
38
+53%
|
34
-11%
|
30
-11%
|
|
| Equity | ||||||||||||||
| Common Stock |
12
|
13
|
13
|
13
|
13
|
13
|
14
|
14
|
14
|
16
|
16
|
16
|
5
|
|
| Retained Earnings |
0
|
1
|
2
|
3
|
2
|
3
|
10
|
7
|
6
|
6
|
8
|
8
|
4
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
1
|
2
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
12
N/A
|
14
+20%
|
11
-21%
|
10
-14%
|
12
+18%
|
16
+39%
|
24
+49%
|
20
-15%
|
7
-67%
|
8
+20%
|
6
-23%
|
7
+19%
|
7
-2%
|
|
| Total Liabilities & Equity |
17
N/A
|
22
+32%
|
22
-2%
|
22
0%
|
24
+11%
|
26
+7%
|
43
+67%
|
44
+2%
|
30
-32%
|
33
+10%
|
45
+35%
|
41
-7%
|
37
-9%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
0
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
3
|
3
|
|